Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Mustang Bio

Status

Terminated

Conditions

Waldenstrom's Macroglobulinemia Refractory

Follicular B-cell Non-Hodgkin's Lymphoma

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Mantle Cell Lymphoma Refractory

Diffuse Large B Cell Lymphoma

Mantle Cell Lymphoma Recurrent

Small Lymphocytic Lymphoma, Relapsed

Hairy Cell Leukemia

Waldenstrom's Macroglobulinemia Recurrent

Chronic Lymphocytic Leukemia in Relapse

B-cell Lymphoma Refractory

Treatments

Biological: Prior MB-106 CAR-T cell investigational product.

Biological: Prior MB-102 CAR-T cell investigational product.

Study type

Observational

Funder types

Industry

Identifiers

NCT05645744

MB100-OBS-001

Details and patient eligibility

About

A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.

Full description

Non-interventional, multi-center, long-term follow-up study of subjects previously treated with a Mustang Bio CAR-T cell investigational product in a Mustang Bio sponsored clinical study. Subjects who enroll will be monitored for a total of up to 15 years from the time of their last investigational product infusion.

Enrollment

3 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients previously treated with a Mustang Bio CAR-T cell investigational product in a prior Mustang Bio sponsored clinical study.
Patient has provided signed and dated informed consent.

Exclusion criteria

None. All patients who have received prior treatment with Mustang Bio CAR-T cell investigational product in a Mustang Bio sponsored clinical study are eligible for this long-term follow up (LTFU) study.